Core Scientific Inc New
Core Scientific Inc New Fundamental Analysis
Core Scientific Inc New (CORZR) shows moderate financial fundamentals with a PE ratio of -18.97, profit margin of -90.47%, and ROE of 34.60%. The company generates $0.3B in annual revenue with weak year-over-year growth of 1.65%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -11.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze CORZR's fundamental strength across five key dimensions:
Efficiency Score
WeakCORZR struggles to generate sufficient returns from assets.
Valuation Score
ExcellentCORZR trades at attractive valuation levels.
Growth Score
WeakCORZR faces weak or negative growth trends.
Financial Health Score
ExcellentCORZR maintains a strong and stable balance sheet.
Profitability Score
WeakCORZR struggles to sustain strong margins.
Key Financial Metrics
Is CORZR Expensive or Cheap?
P/E Ratio
CORZR trades at -18.97 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, CORZR's PEG of -0.05 indicates potential undervaluation.
Price to Book
The market values Core Scientific Inc New at -5.69 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 63.97 times EBITDA. This signals the market has high growth expectations.
How Well Does CORZR Make Money?
Net Profit Margin
For every $100 in sales, Core Scientific Inc New keeps $-90.47 as profit after all expenses.
Operating Margin
Core operations generate -38.03 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $34.60 in profit for every $100 of shareholder equity.
ROA
Core Scientific Inc New generates $-12.29 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Core Scientific Inc New generates strong operating cash flow of $274.66M, reflecting robust business health.
Free Cash Flow
Core Scientific Inc New generates weak or negative free cash flow of $-454.93M, restricting financial flexibility.
FCF Per Share
Each share generates $-1.44 in free cash annually.
FCF Yield
CORZR converts -8.55% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-18.97
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.05
vs 25 benchmark
P/B Ratio
Price to book value ratio
-5.69
vs 25 benchmark
P/S Ratio
Price to sales ratio
16.93
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-1.10
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.15
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.35
vs 25 benchmark
ROA
Return on assets percentage
-0.12
vs 25 benchmark
ROCE
Return on capital employed
-0.08
vs 25 benchmark
How CORZR Stacks Against Its Sector Peers
| Metric | CORZR Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -18.97 | 34.04 | Better (Cheaper) |
| ROE | 34.60% | 1149.00% | Weak |
| Net Margin | -90.47% | -87420.00% (disorted) | Weak |
| Debt/Equity | -1.10 | 7.86 | Strong (Low Leverage) |
| Current Ratio | 1.15 | 5.90 | Neutral |
| ROA | -12.29% | -306991.00% (disorted) | Weak |
CORZR outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Core Scientific Inc New's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
230.94%
Industry Style: Growth, Innovation, High Beta
High GrowthEPS CAGR
-4154.74%
Industry Style: Growth, Innovation, High Beta
DecliningFCF CAGR
2088.79%
Industry Style: Growth, Innovation, High Beta
High Growth